Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Department of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Sci Rep. 2020 Dec 9;10(1):21562. doi: 10.1038/s41598-020-75869-x.
The aim of the present study was to analyze copy number variations (CNV) of multiple oncogenes and tumor suppressor genes in genomic DNA from primary tumor tissue, lymph node metastasis and cell-free DNA (cfDNA) from serum of 72 urothelial carcinoma of bladder (UCB) patients treated with radical cystectomy (RC), using multiplex ligation-dependent probe amplification (MLPA). We hypothesized that primary tumor and lymph node metastasis show similar CNV profiles, and CNV are more present in lymph node metastasis compared to primary tumor tissue. Samples from 43 (59.7%) patients could be analyzed. In total, 35 (83%), 26 (68%) and 8 (42%) patients had CNV in primary tumor, serum and lymph node metastasis, respectively. MYC, CCND1, ERBB2 and CCNE1 displayed the most frequent amplifications. In particular, CNV in ERBB2 was associated with aggressive tumor characteristics. CNV in both ERBB2 and TOP2A were risk factors for disease recurrence. The current findings show that CNV are present in various oncogenes and tumor suppressor genes in genomic DNA from primary tumor, lymph node metastasis and cfDNA from serum. CNV were more present in genomic DNA from primary tumor tissue compared to cfDNA from serum and genomic DNA from lymph node metastasis. Patients with CNV in ERBB2 and TOP2A are at increased risk for disease recurrence following RC. Further studies are necessary to validate, whether these genes may represent promising candidates for targeted-therapy.
本研究的目的是通过多重连接依赖性探针扩增(MLPA)分析 72 例接受根治性膀胱切除术(RC)治疗的膀胱癌(UCB)患者的原发肿瘤组织、淋巴结转移和血清无细胞 DNA(cfDNA)中的多个癌基因和肿瘤抑制基因的拷贝数变异(CNV)。我们假设原发肿瘤和淋巴结转移显示出相似的 CNV 谱,并且 CNV 在淋巴结转移中比原发肿瘤组织更为常见。对 43 例(59.7%)患者的样本进行了分析。总共,35 例(83%)、26 例(68%)和 8 例(42%)患者的原发肿瘤、血清和淋巴结转移中分别存在 CNV。MYC、CCND1、ERBB2 和 CCNE1 显示出最频繁的扩增。特别是,ERBB2 中的 CNV 与侵袭性肿瘤特征相关。ERBB2 和 TOP2A 中的 CNV 都是疾病复发的危险因素。目前的研究结果表明,CNV 存在于原发肿瘤、淋巴结转移的基因组 DNA 中和血清 cfDNA 中的各种癌基因和肿瘤抑制基因中。与血清 cfDNA 相比,原发肿瘤组织中的 CNV 更常见,而与淋巴结转移中的基因组 DNA 相比则较少。ERBB2 和 TOP2A 中存在 CNV 的患者在接受 RC 治疗后疾病复发的风险增加。需要进一步的研究来验证这些基因是否可能是靶向治疗的有前途的候选基因。